Study published in Sci Transl Med. on the effects of A monoclonal antibody targeting nonjunctional claudin-1 in CKD of UUO model.

We introduce a case study of drug efficacy evaluation of anti-claudin-1 antibody using our chronic kidney disease model, UUO model.


Title: A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity

( Roehlen et al., Sci Transl Med. 2022 )   Article Link ► [DOI: 10.1126/scitranslmed.abj4221]


In this study, we administered murineized CLDN1 antibody to the UUO model and evaluated the fibrosis area of renal tissue by sirius red staining and macrophage infiltration by immunostaining.

Treatment with murineized CLDN1 antibody resulted in suppression of fibrosis and macrophage infiltration of renal tissue.


As in this study, the UUO model can be used in studies to evaluate the efficacy of antibody drugs and other test substances on kidney fibrosis, as well as in basic research on chronic kidney disease.


The UUO model shows pathological features of chronic kidney disease such as interstitial fibrosis, tubular atrophy, and inflammatory cell infiltration. And this model has a test duration of 2 weeks, which makes this model suitable for in vivo screening tests of anti-fibrotic drugs for kidney fibrosis.


In our UUO model, one side of the ureter is ligated to induce the disease. The diseased kidney is divided into three sections for analysis such as histopathology, biochemistry and gene expresstion, so various analyses can be performed using the samples from a single mouse.

For more information about our UUO model, please click here ▶▶▶ 【 About UUO Model


If you are interested in our UUO model or other chronic kidney disease models or have any questions, please feel free to contact us.